The Southeast Asia Lornoxicam Market was valued at USD 62.1 million in 2025 and is projected to reach USD 98.7 million by 2032, growing at a Compound Annual Growth Rate (CAGR) of 6.8% during the forecast period (2025–2032). This growth is being driven by the rising prevalence of musculoskeletal disorders, an aging population seeking pain relief, and increasing healthcare expenditure across ASEAN nations, coupled with the expansion of the region’s generic pharmaceutical manufacturing capabilities.

As the pharmaceutical supply chain in Southeast Asia becomes increasingly sophisticated, the spotlight is on the key manufacturers and suppliers of Active Pharmaceutical Ingredients (APIs) who are ensuring the quality, availability, and affordability of essential medications. In this blog, we profile the Top 10 Companies in the Southeast Asia Lornoxicam Industry—a mix of global pharmaceutical giants, leading chemical manufacturers, and regional specialists shaping the future of pain management therapeutics.

---

🔟 10. Hetero Drugs Limited

Headquarters: Hyderabad, Telangana, India
Key Offering: Lornoxicam API, Pharmaceutical Intermediates

Hetero Drugs is one of India’s largest generic pharmaceutical companies and a leading global producer of Active Pharmaceutical Ingredients (APIs). It has established a strong supply footprint in Southeast Asia, providing high-purity Lornoxicam to numerous formulation manufacturers across the region. The company’s vertically integrated model, from API to finished dosage forms, makes it a reliable and cost-competitive partner.

Strategic Initiatives in Southeast Asia:

• Significant API export volumes to Thailand, Indonesia, and Vietnam.
• Focus on regulatory compliance to meet stringent ASEAN market standards.
• Investment in advanced R&D for process optimization and impurity profiling.

Download FREE Sample Report: Southeast Asia Lornoxicam Market – View in Detailed Research Report

---

9️⃣ 9. Zhejiang Jiuzhou Pharmaceutical Co., Ltd.

Headquarters: Taizhou, Zhejiang, China
Key Offering: High-Purity Lornoxicam (>99%), Chemical Intermediates

Zhejiang Jiuzhou Pharmaceutical is a prominent Chinese manufacturer specializing in pharmaceutical intermediates and APIs, including Lornoxicam. The company has become a key supplier to the Southeast Asian market, leveraging its scale and efficient production capabilities to offer competitive pricing, which is particularly impactful in price-sensitive regional segments.

Strategic Initiatives in Southeast Asia:

• Active participation in regional pharmaceutical trade exhibitions and B2B platforms.
• Building relationships with distributors and large generic drug makers in Malaysia and the Philippines.
• Ensuring product certifications align with international pharmacopoeia standards.

---

8️⃣ 8. Duopharma Biotech Berhad

Headquarters: Kuala Lumpur, Malaysia
Key Offering: Finished Lornoxicam formulations, Contract Manufacturing

Duopharma Biotech is a leading Malaysian pharmaceutical company with a significant presence in the domestic and regional markets. While primarily a formulator, its strategic procurement and integration of Lornoxicam API into its extensive portfolio of generic medicines, including pain management drugs, make it a pivotal player in the local market value chain.

Strategic Initiatives in Southeast Asia:

• Strong distribution network across Malaysia and neighboring countries.
• Focus on supplying affordable generic medicines to public healthcare sectors.
• Engagement in government tenders and essential drug list programs.

---

7️⃣ 7. PT. Kalbe Farma Tbk

Headquarters: Jakarta, Indonesia
Key Offering: Branded and Generic Lornoxicam products

PT. Kalbe Farma is Indonesia’s largest pharmaceutical company and a major force in the Southeast Asian market. It is a significant end-user and distributor of Lornoxicam API, which it incorporates into its wide range of prescription and over-the-counter analgesic products. The company’s deep understanding of local market dynamics and extensive retail penetration drives consistent API demand.

Strategic Initiatives in Southeast Asia:

• Dominant market share in Indonesia’s pharmaceutical retail sector.
• Strategic long-term supply agreements with international API producers.
• Investment in local manufacturing and packaging facilities.

---

6️⃣ 6. Sanofi

Headquarters: Paris, France
Key Offering: Innovative and established pharmaceutical brands

Sanofi, a global healthcare leader, maintains a significant presence in Southeast Asia through its diverse portfolio, which includes pain management therapies. While not a primary API manufacturer of Lornoxicam, the company influences the market through its branded formulations and clinical expertise, setting standards for quality and therapeutic use that impact regional prescribing practices and API quality expectations.

Strategic Initiatives in Southeast Asia:

• Promotion of responsible pain management protocols among healthcare professionals.
• Partnerships with local healthcare institutions and governments.
• Commitment to sustainable and ethical supply chain practices.

Download FREE Sample Report: Southeast Asia Lornoxicam Market – View in Detailed Research Report

---

5️⃣ 5. GlaxoSmithKline plc (GSK)

Headquarters: London, United Kingdom
Key Offering: Over-the-counter (OTC) analgesics, Prescription drugs

GSK is a major multinational with a strong commercial footprint in Southeast Asia. Its consumer healthcare division markets leading OTC pain relief brands, while its pharmaceuticals division promotes prescription medicines. GSK’s market activities and sourcing strategies for analgesic ingredients, including potential use of Lornoxicam in specific formulations, contribute to the overall market dynamics and quality benchmarks.

Strategic Initiatives in Southeast Asia:

• Extensive marketing and consumer education campaigns on pain management.
• Robust pharmacovigilance and drug safety monitoring systems.
• Investment in local manufacturing and supply chain logistics.

---

4️⃣ 4. Novartis AG

Headquarters: Basel, Switzerland
Key Offering: Innovative medicines, Generic pharmaceuticals (via Sandoz)

Novartis, through its generics division Sandoz, is a critical player in the global and regional supply of affordable generic medicines. While its direct involvement in Lornoxicam API manufacturing may be limited, Sandoz’s formidable position as a global generics company influences sourcing patterns, pricing, and quality standards for APIs like Lornoxicam used by its network of manufacturers and partners across Southeast Asia.

Strategic Initiatives in Southeast Asia:

• Leadership in the generic pharmaceuticals segment across multiple ASEAN markets.
• Advocacy for policies that improve access to essential medicines.
• Focus on supply chain resilience and diversified sourcing.

---

3️⃣ 3. Pfizer Inc.

Headquarters: New York City, New York, USA
Key Offering: Broad portfolio of prescription drugs, including analgesics

Pfizer’s legacy and ongoing presence in the pain management therapeutic area give it substantial influence in the Southeast Asian pharmaceutical landscape. The company’s high standards for API quality and safety, along with its extensive clinical research, help shape regulatory and medical community expectations for drugs like Lornoxicam, indirectly guiding the specifications demanded from API suppliers in the region.

Strategic Initiatives in Southeast Asia:

• Continuous medical education programs for healthcare providers.
• Strong regulatory affairs teams ensuring compliance in each country.
• Commitment to ethical marketing and anti-counterfeiting measures.

---

2️⃣ 2. Teva Pharmaceutical Industries Ltd.

Headquarters: Tel Aviv, Israel
Key Offering: Generic pharmaceuticals, Active Pharmaceutical Ingredients (APIs)

Teva is one of the world’s largest generic drug manufacturers and a significant global supplier of APIs. The company has a strategic interest in the Southeast Asian market and is a potential key supplier of Lornoxicam API to regional formulators. Its immense scale, integrated supply chain, and focus on complex generics make it a formidable force in the API market.

Strategic Initiatives in Southeast Asia:

• Global API supply chain with capabilities to serve high-volume demand.
• Focus on strategic partnerships with local generic companies.
• Investment in ensuring cGMP (current Good Manufacturing Practice) compliance for all markets.

---

1️⃣ 1. Mylan N.V. (now part of Viatris)

Headquarters: Canonsburg, Pennsylvania, USA (Global)
Key Offering: Extensive portfolio of generic drugs and APIs

Viatris, formed from the merger of Mylan and Upjohn, is a global powerhouse in generic and branded medicines. Mylan’s legacy as a top-tier API manufacturer and generic formulator positions Viatris as a central influencer in the Southeast Asia Lornoxicam market. The company’s integrated model, from API production to finished product distribution, ensures a consistent and quality-assured supply chain for essential medicines like those containing Lornoxicam.

Strategic Initiatives in Southeast Asia:

• One of the world’s leading producers of active pharmaceutical ingredients.
• Deep regional presence with manufacturing and distribution facilities.
• Commitment to expanding access to high-quality affordable medicines across ASEAN.

Get Full Report Here: Southeast Asia Lornoxicam Market – View in Detailed Research Report

---

🌟 Outlook: The Future of the Lornoxicam Market in Southeast Asia is Strategic and Quality-Centric

The Southeast Asia Lornoxicam market is undergoing a significant transformation. While generic competition and price sensitivity persist, the industry is witnessing a decisive shift towards higher quality standards, supply chain resilience, and strategic regional integration to meet the growing healthcare demands of a developing population.

📈 Key Trends Shaping the Market:

• Regulatory Harmonization: Efforts within ASEAN towards aligning pharmaceutical regulations are streamlining API registration, though country-specific requirements remain a challenge.
• Preference for High-Purity APIs: Stringent quality controls and the pursuit of international market approvals are driving demand for Lornoxicam with purity >99%.
• Supply Chain Localization: Governments are incentivizing local pharmaceutical production to reduce import dependency, influencing API sourcing strategies.
• Rising Chronic Disease Burden: The increasing prevalence of arthritis and age-related pain conditions ensures sustained therapeutic demand for effective NSAIDs like Lornoxicam.

Get Full Report Here: Southeast Asia Lornoxicam Market – View in Detailed Research Report

The companies listed above are not only supplying a critical pharmaceutical ingredient—they are enabling the accessibility and affordability of essential pain management therapies for millions across Southeast Asia.

---

About 24chemicalresearch: 24chemicalresearch is a leading provider of market research reports and business intelligence, with a deep focus on the chemical and material sectors. Our reports offer data-driven insights, competitive analysis, and market forecasts to help businesses navigate complex industries and make informed strategic decisions.